increas
avail
nucleic
acid
amplif
test
sinc
revolutionis
understand
pathogenesi
epidemiolog
clinic
laboratori
aspect
known
novel
viral
respiratori
pathogen
highthroughput
multiplex
polymeras
chain
reaction
commonli
use
qualit
detect
method
utilis
newer
techniqu
nextgener
sequenc
becom
common
follow
signific
cost
reduct
rapid
readili
access
isotherm
amplif
platform
also
allow
molecular
diagnost
use
pointofcar
format
review
focus
current
applic
limit
molecular
diagnosi
respiratori
virus
although
imperfect
high
throughput
multiplex
naat
assay
target
differ
virus
like
commonli
use
method
diagnosi
viral
respiratori
infect
short
medium
term
nucleic
acid
extractionindepend
lamp
assay
promis
limit
rang
virus
detect
perform
lamp
assay
remain
suboptim
compar
rtpcr
present
near
futur
diagnost
virolog
laboratori
face
increas
pressur
provid
specif
viral
aetiolog
respiratori
infect
within
clinic
relev
timefram
facilit
target
antivir
therapi
conflict
interest
sourc
fund
author
state
conflict
interest
disclos
worldwid
viral
respiratori
tract
infect
caus
signific
morbid
mortal
unit
state
america
usa
pneumonia
influenza
rank
sixth
caus
hospitalis
among
medicar
beneficiari
new
south
wale
australia
influenza
pneumonia
respons
total
death
howev
like
underestim
true
burden
influenza
unrecognis
infect
may
result
respiratori
cardiovascular
hospitalis
death
similarli
respiratori
virus
may
also
caus
sever
respiratori
infect
particularli
young
elderli
immunocompromis
laboratori
confirm
aetiolog
viral
respiratori
tract
infect
guid
treatment
obviat
need
unnecessari
test
use
epidemiolog
purpos
includ
plan
vaccin
strategi
select
appropri
test
clinician
consid
avail
perform
turnaround
time
differ
diagnost
method
although
viral
cultur
remain
gold
standard
diagnosi
nucleic
acid
amplif
test
naat
predominantli
use
given
increas
sensit
specif
breadth
reduc
turnaround
time
pathogen
detect
naat
also
use
type
subtyp
quantit
viral
load
detect
antivir
resist
nevertheless
naat
perfect
role
laboratori
diagnosi
respiratori
virus
constantli
evolv
herein
discuss
applic
advantag
limit
naat
diagnos
clinic
manag
respiratori
virus
naat
primarili
use
determin
respiratori
virus
respons
infect
viral
aetiolog
unlik
reliabl
distinguish
clinic
featur
alon
tabl
outlin
respiratori
virus
commonli
detect
use
naat
although
routin
perform
quantit
detect
may
provid
use
inform
sever
prognosi
viral
respiratori
infect
efficaci
resist
develop
antivir
therapi
durat
viral
shed
inform
infect
control
measur
hospitalis
adult
influenza
infect
viral
rna
detect
serv
surrog
persist
isol
viru
thu
enabl
identif
risk
factor
sever
infect
pathogenesi
novel
emerg
respiratori
virus
may
guid
studi
viral
replic
exampl
time
differ
patient
group
adult
paediatr
immunocompet
immunosuppress
relat
symptomatolog
respons
treatment
differ
tissu
differ
locat
respiratori
tract
paediatr
popul
quantit
respiratori
virus
may
use
differenti
clinic
signific
infect
versu
asymptomat
infect
carriag
quantit
also
use
understand
clinic
impact
coinfect
includ
pathogen
frequent
detect
virus
human
bocaviru
hbov
polyomavirus
durat
antivir
therapi
influenza
viru
infect
may
also
optimis
viral
load
measur
howev
accur
quantit
viral
load
may
compromis
nonuniform
sampl
volum
sampl
like
nose
throat
swab
nt
although
neuraminidas
inhibitor
ni
wide
prescrib
influenza
infect
number
antivir
current
phase
ii
iii
trial
noninfluenza
virus
detect
antivir
resist
best
describ
ni
near
resist
season
influenza
strain
oseltamivir
prior
influenza
pandem
influenza
subtyp
replac
viru
influenza
subtyp
remain
mostli
ni
suscept
oseltamivir
resist
like
develop
subject
given
oseltamivir
prophylaxi
immunocompromis
patient
prolong
viral
shed
oseltamivir
resist
often
associ
histidin
tyrosin
amino
acid
substitut
posit
neuraminidas
gene
influenza
virus
glutamin
valin
substitut
arginin
lysin
substitut
posit
respect
influenza
virus
substitut
identifi
includ
isoleucin
arginin
lysin
valin
posit
serin
asparaginas
posit
isoleucin
valin
posit
substitut
combin
confer
even
higher
level
resist
ni
antivir
resist
determin
use
variou
naat
method
includ
revers
transcript
polymeras
chain
reaction
rtpcr
roll
circl
amplif
sequenc
techniqu
high
resolut
melt
hrm
analysi
pyrosequenc
wide
use
clinic
virolog
laboratori
compar
convent
nextgener
sequenc
ng
use
detect
singl
nucleotid
polymorph
snp
outlin
compar
hrm
analysi
pyrosequenc
ad
advantag
estim
rel
proport
suscept
wildtyp
resist
mutant
virus
mix
popul
sampl
epidemiolog
phylogenet
type
naat
use
explor
genom
relationship
exist
novel
respiratori
virus
analys
allow
greater
resolut
within
speci
type
determin
origin
evolut
respiratori
virus
aid
outbreak
investig
demonstr
transmiss
event
advanc
pathogen
understand
guid
discoveri
subsequ
detect
antivir
resist
assess
vaccin
effect
molecular
type
method
gener
involv
pcr
follow
nucleotid
sequenc
partial
whole
genom
year
period
phylogenet
analysi
complet
genom
influenza
virus
demonstr
presenc
multipl
clade
cocircul
new
york
state
multipl
lineag
common
haemagglutinin
gene
ancestor
circul
follow
distinct
reassort
event
japanes
hospit
investig
demonstr
nosocomi
transmiss
two
genet
distinct
influenza
variant
analys
haemagglutinin
sequenc
week
period
data
use
identifi
laps
reaffirm
import
stricter
infect
control
measur
full
length
analys
neuraminidas
haemagglutinin
gene
influenza
virus
influenza
season
show
distinct
compar
virus
circul
influenza
pandem
associ
virus
collect
newcastl
australia
time
transmiss
oseltamivir
resist
virus
commun
similar
techniqu
also
identifi
circul
pattern
influenza
b
virus
observ
assist
understand
influenza
vaccin
composit
effect
specimen
collect
preanalyt
issu
naat
perform
upper
lower
respiratori
tract
sampl
includ
nt
nasopharyng
swab
nasopharyng
aspir
npa
throat
gargl
bronchoalveolar
lavag
fluid
pleural
fluid
sputum
prefer
specimen
due
viscos
recent
studi
show
higher
mean
viral
load
influenza
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
sputa
process
use
dunk
swirl
method
compar
nt
method
involv
dunk
steril
swab
sputum
swirl
swab
steril
water
subsequ
process
respiratori
specimen
type
age
subject
test
affect
perform
naat
sensit
naat
may
increas
lower
respiratori
tract
paediatr
sampl
test
detect
virus
respiratori
sampl
also
affect
time
onset
symptom
specimen
collect
respiratori
virus
like
detect
specimen
collect
soon
symptom
onset
viral
load
gener
higher
earli
ill
especi
paediatr
sampl
qualiti
sampl
collect
especi
import
respiratori
tract
infect
train
sampl
recommend
howev
patient
selfcollect
sampl
throat
wash
sever
acut
respiratori
syndromecoronaviru
sarscov
infect
may
reduc
transmiss
risk
healthcar
worker
test
stool
may
complement
test
respiratori
sampl
virus
abl
replic
outsid
respiratori
tract
sarscov
rna
detect
stool
respiratori
sampl
week
symptom
onset
whilst
avian
influenza
rna
human
season
influenza
virus
detect
stool
sampl
quantit
rsv
rna
blood
collect
patient
undergon
haematopoiet
stem
cell
transplant
hsct
may
also
predict
poor
outcom
guid
antivir
therapi
volum
method
nucleic
acid
extract
submit
specimen
also
affect
naat
perform
differ
extract
method
may
suit
recov
rna
dna
total
nucleic
acid
recent
commerci
extractionindepend
assay
detect
influenza
multipl
naat
method
use
diagnost
virolog
laboratori
diagnosi
viral
aetiolog
respiratori
infect
includ
pcr
rtpcr
realtim
rtpcr
rrtpcr
convent
sanger
sequenc
pyrosequenc
pcr
coupl
mass
spectrometri
microarray
techniqu
rtpcr
commonli
employ
qualit
method
detect
respiratori
virus
commerci
rrtpcr
platform
compar
sensit
detect
respiratori
virus
although
except
commerci
assay
target
human
rhinoviru
hrv
may
reliabl
differenti
hrv
human
enteroviru
hev
within
picornavirida
famili
commerci
rrtpcr
platform
may
also
lack
sensit
detect
certain
hrv
human
adenoviru
hadv
subtyp
nest
pcr
two
amplif
reaction
perform
sequenti
either
one
heminest
two
fulli
nest
primer
locat
relat
first
primer
set
gener
sensit
expens
increas
risk
contamin
contrast
singleplex
duplex
assay
multiplex
pcr
allow
simultan
detect
differ
respiratori
virus
virus
influenza
may
also
type
subtyp
bacteri
target
bordetella
pertussi
mycoplasma
pneumonia
chlamydophila
pneumonia
also
includ
commerci
multiplex
respiratori
viru
pcr
similar
approach
use
detect
bacteri
pathogen
complic
respiratori
viral
infect
limit
number
multiplex
reaction
three
four
target
may
improv
sensit
elimin
primer
dimeris
competit
multipl
target
although
newer
assay
use
pcr
melt
curv
analysi
filmarray
ausdiagnost
microcapillari
electrophoresi
seeplex
respifind
iceplex
microspher
hybridis
associ
flow
cytomet
detect
led
camera
detect
barcod
detect
xtag
rvp
resplex
ii
multicodeplx
solid
phase
hybridis
microarray
infin
ngen
verigen
icub
esensor
pcr
coupl
electrospray
ionis
mass
spectrometri
plexid
allow
multiplex
viral
target
good
sensit
high
resolut
melt
analysi
hrm
analysi
base
dissoci
behaviour
dna
transit
doubleto
singlestrand
statu
presenc
dna
intercal
dye
detect
differ
pcr
amplicon
base
sequenc
length
base
composit
g
c
content
strand
base
pair
hrm
analysi
use
pathogen
identif
speci
identif
genotyp
detect
snp
use
influenza
type
also
determin
antivir
resist
detect
mutat
hrm
rel
simpl
cheap
perform
use
standard
equip
laboratori
offer
naat
howev
snp
larger
amplicon
bp
readili
discern
compar
smaller
fragment
consist
detect
limit
hrm
allel
differ
basi
length
variabl
number
tandem
repeat
may
readili
resolv
repeat
number
variat
chang
g
c
amplim
appreci
size
loopmedi
isotherm
amplif
lamp
reli
autocycl
strand
displac
gener
dna
rna
use
revers
transcriptas
isotherm
amplif
use
detect
sever
respiratori
virus
includ
human
avian
influenza
virus
rsv
hmpv
human
middl
east
respiratori
syndrom
coronaviru
merscov
unlik
rrtpcr
lamp
assay
optim
detect
multipl
respiratori
virus
simultan
howev
influenza
viru
b
detect
use
two
templat
three
enzym
thermost
dna
polymeras
revers
transcriptas
thermost
nick
endonucleas
absenc
thermal
cycl
use
specialis
equip
highli
specif
lamp
assay
perform
use
small
footprint
benchtop
instrument
aler
influenza
b
aler
usa
whilst
assay
less
sensit
rrtpcr
rapid
turnaround
time
minut
allow
use
pointofcar
test
recent
evalu
lamp
use
six
primer
target
matrix
gene
rsv
polymeras
gene
rsv
b
compar
rtpcr
detect
rsv
show
concord
simpl
amplificationbas
nucleic
acid
sequencebas
roll
circl
amplif
assay
simpl
amplificationbas
assay
samba
nucleic
acid
sequencebas
amplif
nasba
roll
circl
amplif
rca
three
isotherm
amplif
method
develop
wide
use
detect
respiratori
virus
altern
rrtpcr
influenza
amplicon
visual
detect
use
test
strip
follow
nucleic
acid
extract
simpl
amplif
perform
samba
compar
rrtpcr
turnaround
time
reduc
recent
studi
determin
limit
detect
influenza
b
viru
use
samba
copi
copi
respect
multiplex
nasba
assay
develop
detect
influenza
b
virus
parainfluenzaviru
piv
rsv
rubella
viru
coxsacki
virus
use
enzymelink
oligonucleotid
captur
optic
detect
calcul
time
posit
quantit
human
rhinoviru
also
achiev
use
nasba
rca
anoth
isotherm
amplif
method
utilis
circularis
oligonucleotid
detect
target
nucleic
acid
sequenc
dna
ligas
join
two
end
juxtapos
probe
upon
hybridis
target
dna
rna
sequenc
creat
templat
exponenti
roll
circl
amplif
reaction
method
use
qualit
detect
respiratori
virus
detect
ni
resist
confer
previous
identifi
snp
polymeras
chain
reaction
coupl
electrospray
ionisationmass
spectrometri
matrixassist
laser
desorpt
ionisationtim
flight
sequenc
mass
spectrometri
method
beyond
scope
review
gener
use
routin
virolog
diagnost
laboratori
method
detail
previous
employ
pcr
prior
mass
spectrometri
analysi
rtpcr
esim
maldi
sequenc
previous
use
identif
virus
subtyp
human
avian
influenza
virus
elucid
rout
introduct
subsequ
transmiss
sarscov
studi
evolut
singl
nucleotid
variant
viral
isol
ng
larg
supersed
techniqu
inhous
versu
commerci
assay
qualiti
assur
naat
assay
diagnosi
respiratori
virus
avail
commerci
may
develop
inhous
qualit
commerci
assay
subject
stringent
conform
assess
approv
diagnost
use
relev
administr
author
food
drug
administr
fda
usa
ce
european
union
australia
inhous
develop
naat
subject
regulatori
requir
therapeut
good
administr
tga
inhous
naat
assay
develop
refer
genom
sequenc
previous
determin
assay
gener
cheaper
commerci
naat
although
latter
typic
easier
oper
open
platform
inhous
develop
assay
ad
advantag
flexibl
adapt
eas
troubleshoot
flexibl
especi
use
new
virus
emerg
human
popul
howev
requir
use
specialis
equip
technic
expertis
make
unsuit
pointofcar
test
constant
review
assay
perform
import
ensur
optim
sensit
given
chang
epidemiolog
circul
virus
particularli
import
annual
antigen
drift
influenza
virus
valid
differ
target
multiplex
assay
assay
develop
may
challeng
commerci
black
box
close
platform
simpl
oper
offer
conveni
smaller
laboratori
lack
sophist
equip
expertis
oligonucleotid
primer
probe
use
typic
publish
due
commerci
confidenti
commerci
assay
also
unlik
develop
earli
phase
newli
circul
viru
exampl
commerci
naat
virus
detect
provid
tabl
extern
qualiti
assess
necessari
ensur
satisfactori
perform
naat
time
write
royal
colleg
pathologist
australasia
rcpa
provid
qualiti
assur
program
specif
molecular
diagnosi
respiratori
virus
howev
qualiti
control
molecular
diagnost
qcmd
respiratori
diseas
program
includ
qualit
assess
virus
commonli
associ
respiratori
infect
includ
influenza
viru
piv
rsv
hrv
hmpv
coronaviru
hadv
argument
naat
sensit
gold
standard
cellcultur
method
diagnosi
respiratori
virus
specif
antigen
detect
test
includ
immunochromatograph
immunofluoresc
assay
naat
crucial
viru
cultur
perform
highthroughput
autom
easi
use
multiplex
assay
place
naat
diagnost
forefront
develop
countri
cost
may
less
concern
use
multiplex
pcr
facilit
studi
impact
viral
andor
bacteri
coinfect
sever
respiratori
infect
heterogen
assay
popul
studi
make
difficult
draw
definit
conclus
util
naat
manag
viral
respiratori
infect
increas
sensit
significantli
reduc
turnaround
time
naat
compar
viral
cultur
improv
patient
care
guid
antivir
therapi
although
studi
demonstr
benefit
naat
reduc
prescript
antibiot
viral
respiratori
infect
other
fail
show
signific
reduct
test
antibiot
cost
hospit
length
stay
despit
increas
viral
diagnost
yield
yet
unexplor
clinic
impact
lamp
assay
compar
turnaround
time
rapid
influenza
diagnost
test
reduc
unnecessari
ancillari
test
antibiot
prescript
increas
antivir
prescript
use
emerg
depart
furthermor
clinic
financi
benefit
deriv
naat
benefit
clinician
may
seen
laboratori
cost
main
limit
widespread
use
naat
diagnos
viral
respiratori
infect
present
black
box
close
platform
may
offer
throughput
requir
rang
virus
detect
may
inadequ
exampl
singlesampl
loopmedi
isotherm
aler
influenza
b
assay
abl
detect
influenza
virus
sensit
naat
affect
mutat
primer
probe
bind
region
virus
subject
genom
drift
potenti
reassort
recombin
influenza
enterovirus
period
reevalu
assay
qualiti
assur
program
therefor
paramount
ensur
optimum
perform
novel
virus
variant
reassort
virus
may
alway
identifi
pcr
reli
priori
sequenc
virus
gener
lack
univers
conserv
genet
region
ribosom
rna
present
bacteria
fungi
although
degener
primer
may
occasion
target
conserv
region
within
relat
viru
group
although
may
overcom
sequenc
method
isol
novel
viru
instrument
develop
naat
test
method
includ
serolog
facilit
rapid
diagnosi
pathogen
naat
may
also
lack
specif
particularli
children
multipl
virus
may
detect
multiplex
rtpcr
assay
use
children
naat
result
requir
cautiou
interpret
given
high
detect
rate
respiratori
virus
asymptomat
subject
natur
current
naat
rel
close
term
pathogen
detect
ng
assist
issu
still
remain
reach
routin
laboratori
therefor
open
test
includ
viru
isol
electron
microscopi
pathogenspecif
serolog
still
need
detect
novel
pathogen
eg
sarscov
merscov
subtyp
eg
influenza
method
gener
avail
refer
laboratori
serolog
option
respiratori
sampl
collect
late
clinic
cours
epidemiolog
studi
